Author: Widagdo, W.; Okba, Nisreen M.A.; Stalin Raj, V.; Haagmans, Bart L.
Title: MERS-coronavirus: From discovery to intervention Document date: 2016_12_23
ID: 3uyuwzyr_15
Snippet: Besides these prophylactic measures, vaccines could also be applied in particular risk groups. Many different approaches have been taken to develop MERS vaccines (reviewed in [27] ). An orthopoxvirus-based vaccine using modified vaccinia Ankara (MVA) expressing the spike protein has been developed and shown to induce neutralizing antibodies and specific cytotoxic T cell response against MERS-CoV [64] . The MVA itself has been validated as an effe.....
Document: Besides these prophylactic measures, vaccines could also be applied in particular risk groups. Many different approaches have been taken to develop MERS vaccines (reviewed in [27] ). An orthopoxvirus-based vaccine using modified vaccinia Ankara (MVA) expressing the spike protein has been developed and shown to induce neutralizing antibodies and specific cytotoxic T cell response against MERS-CoV [64] . The MVA itself has been validated as an effective vaccine platform in humans [65] . Unlike prophylactic regimens, protection induced by vaccine intervention is long lasting, although not immediate. Thus vaccination would be more appropriate for camel shepherds and slaughterhouse workers who are at a continuous risk of being infected by MERS-CoV from the animals.
Search related documents:
Co phrase search for related documents- animal MERS CoV infect and spike protein: 1, 2
- cell response and human vaccine platform: 1, 2, 3
- cell response and long last: 1, 2
- cell response and MERS CoV infect: 1
- cell response and neutralize antibody: 1
- cell response and risk group: 1, 2, 3, 4
- cell response and spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- cell response and spike protein express: 1, 2
- cell response and vaccine intervention: 1
- cell response and vaccine platform: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- continuous risk and risk group: 1, 2
- different approach and spike protein: 1, 2, 3, 4, 5, 6, 7
- human vaccine platform and neutralize antibody: 1
- human vaccine platform and spike protein: 1, 2, 3
- human vaccine platform and vaccine platform: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Co phrase search for related documents, hyperlinks ordered by date